GREY:IPHAF - Post by User
Post by
blogon Jul 10, 2006 7:00pm
303 Views
Post# 11085122
Difficulties
DifficultiesDoes anyone else find it strange that Lux can get 36 million to test ISA247 on people’s eyes and were having difficulties getting decent financing and a psoriasis deal?
Opportunity d’Lux
Seeing an opportunity to pick up where an older generation of calcineurin inhibitors leave off, Lux Biosciences Inc. recently licensed ophthalmic rights to Isotechnika Inc.’s optimized cyclosporine candidate. Based on the strength of the idea, the company raised $36 million in venture money that it will use to conduct a pivotal Phase II/III trial of ISA247 to treat uveitis starting early next year.